Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBarts & The London NHS Trust
About this trial
Patients living with diabetes mellitus have double the risk of kidney failure compared to patients without diabetes following use of dye in many x-rays and procedures to diagnose and treat narrowing of the arteries (blood vessels) in the heart that can lead to angina or a heart attack. Heart disease is the commonest cause of death in patients with diabetes. People with diabetes are more likely to need these tests/treatments. By identifying those at greater risk of kidney complications we may be able to make these tests/treatments safer and offer them to more patients with diabetes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age > 18 years, known diabetes mellitus or BM on arrival consistent with probable diagnosis of diabetes, eGFR <60 ml/min
Undergoing a PCI procedure
Agrees to the additional collection of blood and urine samples as outlined above
Agrees to access of their clinical records for the collection of relevant medical data
Disqualifiers
Cardiogenic shock
Pregnancy
Patient on renal replacement therapy (haemodialysis/CAPD/renal transplant)
Known clinically significant infection such as HIV, Hepatitis or TB
Trial population
Patients with diabetes mellitus and renal impairment
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
250 Participants
are grouped into 1 trial groupGroup A: Diabetes mellitus, renal impairment
Trial outcomes
Primary outcomes
1
Development of contrast induced nephropathy (CIN) which will be defined as an increase in Cr of ≥ 44 μmol/l within 72 hours post-procedure.
Time frame
up to 72 hoursSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov